Key facts
- 52-week range (closes)
- $407.90 – $557.96 Lowest close Oct 15, 2025, highest Sep 3, 2026; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
- Fiscal year ends
- December Fiscal 2025 ended Dec 31, 2025, from SEC filings
- In the S&P 500 since
- Sep 20, 2013 · All S&P 500 changes
- In the Nasdaq-100 since
- before 2007 · All Nasdaq-100 changes
- Analyst coverage
- 4 open price targets from 4 firms: BMO Capital Markets, H.C. Wainwright, UBS, Wolfe Research Approved targets tracked here; see the analyst section below
Vertex Pharmaceuticals (VRTX) is trading up at $510.67 (+1.74%) on NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Analyst price targets on VRTX
Current price targets from 4 firms average $605, median $608, ranging from $562 to $641 — the average is 18% above the current $511. Each is tracked to its date and scored the same way a member's call is.
- UBS $528 → $615 by Sep 2027 Sep 28, 2026 via Investing.com · UBS's track record
- H.C. Wainwright $515 → $641 by Sep 2027 Sep 22, 2026 via Investing.com · H.C. Wainwright's track record
- BMO Capital Markets $515 → $600 by Sep 2027 Sep 22, 2026 via Investing.com · BMO Capital Markets's track record
- Wolfe Research $524 → $562 by Aug 2027 Aug 10, 2026 via Investing.com · Wolfe Research's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Vertex Pharmaceuticals revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.70B | $2.49B | $3.05B | $4.16B | $6.21B | $7.57B | $8.93B | $9.87B | $11.0B | $12.0B |
| Growth (year over year) | +64.9% | +46.2% | +22.5% | +36.6% | +49.1% | +22.1% | +17.9% | +10.5% | +11.7% | +8.9% |
| Gross profit | $1.49B | $2.21B | $2.64B | $3.62B | $5.47B | $6.67B | $7.85B | $8.61B | $9.49B | $10.3B |
| Gross margin | 87.6% | 88.9% | 86.6% | 86.8% | 88.1% | 88.1% | 87.9% | 87.2% | 86.1% | 86.2% |
| Operating income | $9.94M | $123.2M | $635.1M | $1.20B | $2.86B | $2.78B | $4.31B | $3.83B | −$232.9M | $4.17B |
| Operating margin | 0.6% | 5.0% | 20.8% | 28.8% | 46.0% | 36.7% | 48.2% | 38.8% | −2.1% | 34.8% |
| Net income | −$112.1M | $263.5M | $2.10B | $1.18B | $2.71B | $2.34B | $3.32B | $3.62B | −$535.6M | $3.95B |
| Net margin | −6.6% | 10.6% | 68.8% | 28.3% | 43.7% | 30.9% | 37.2% | 36.7% | −4.9% | 32.9% |
| EPS (diluted) | −$0.46 | $1.04 | $8.09 | $4.51 | $10.29 | $9.01 | $12.82 | $13.89 | −$2.08 | $15.32 |
| Balance sheet | ||||||||||
| Cash and equivalents | $1.18B | $1.67B | $2.65B | $3.11B | $5.99B | $6.79B | $10.5B | $10.4B | $4.57B | $5.08B |
| Total assets | $2.90B | $3.56B | $6.26B | $8.32B | $11.8B | $13.4B | $18.2B | $22.7B | $22.5B | $25.6B |
| Total liabilities | $1.56B | $1.50B | $1.81B | $2.23B | $3.06B | $3.33B | $4.24B | $5.15B | $6.12B | $6.98B |
| Shareholders' equity | $1.16B | $2.03B | $4.44B | $6.09B | $8.69B | $10.1B | $13.9B | $17.6B | $16.4B | $18.7B |
| Cash flow | ||||||||||
| Operating cash flow | $236.1M | $844.9M | $1.27B | $1.57B | $3.25B | $2.64B | $4.13B | $3.54B | −$492.6M | $3.63B |
| Capital expenditure | $56.6M | $99.4M | $95.4M | $75.4M | $259.8M | $235.0M | $204.7M | $200.4M | $297.7M | $437.6M |
| Free cash flow | $179.5M | $745.5M | $1.17B | $1.49B | $2.99B | $2.41B | $3.93B | $3.34B | −$790.3M | $3.19B |
| Share buybacks | $0 | $0 | $350.0M | $186.0M | $539.1M | $1.43B | $0 | $427.6M | $1.18B | $2.02B |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.77B | $2.91B | $2.77B | $2.96B | $3.08B | $3.19B | $2.99B | $3.33B |
| Growth (year over year) | +11.6% | +15.7% | +3.0% | +12.1% | +11.0% | +9.5% | +7.8% | +12.5% |
| Gross profit | $2.38B | $2.49B | $2.41B | $2.56B | $2.66B | $2.72B | $2.59B | $2.84B |
| Gross margin | 85.8% | 85.5% | 86.9% | 86.3% | 86.5% | 85.4% | 86.8% | 85.3% |
| Operating income | $1.12B | $1.03B | $630.1M | $1.15B | $1.19B | $1.21B | $1.14B | $1.25B |
| Operating margin | 40.3% | 35.2% | 22.7% | 38.8% | 38.6% | 37.8% | 38.1% | 37.4% |
| Net income | $1.05B | $913.0M | $646.3M | $1.03B | $1.08B | $1.19B | $1.03B | $1.10B |
| Net margin | 37.7% | 31.4% | 23.3% | 34.8% | 35.2% | 37.3% | 34.5% | 33.0% |
| EPS (diluted) | $4.01 | $3.62 | $2.49 | $3.99 | $4.20 | $4.64 | $4.02 | $4.31 |
| Balance sheet | ||||||||
| Cash and equivalents | $5.24B | $4.57B | $4.67B | $4.97B | $4.94B | $5.08B | $5.49B | $6.14B |
| Total assets | $22.2B | $22.5B | $22.9B | $24.0B | $24.9B | $25.6B | $26.5B | $27.4B |
| Total liabilities | $6.61B | $6.12B | $6.38B | $6.86B | $7.54B | $6.98B | $7.12B | $7.18B |
| Shareholders' equity | $15.6B | $16.4B | $16.5B | $17.2B | $17.3B | $18.7B | $19.4B | $20.2B |
| Cash flow | ||||||||
| Operating cash flow | $1.37B | $584.6M | $818.9M | $1.07B | $1.24B | $498.0M | $1.43B | $1.13B |
| Capital expenditure | $67.7M | $92.6M | $40.7M | $145.7M | $101.8M | $149.4M | $133.4M | $112.2M |
| Free cash flow | $1.30B | $492.0M | $778.2M | $927.4M | $1.14B | $348.6M | $1.29B | $1.01B |
| Share buybacks | $307.7M | $417.9M | $426.1M | $391.8M | $1.07B | $128.4M | $336.9M | $469.5M |
From Vertex Pharmaceuticals's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Vertex Pharmaceuticals vs the Health Care sector and the S&P 500
Vertex Pharmaceuticals's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.
| Measure | Vertex Pharmaceuticals | Health Care (59 other S&P 500 companies) | S&P 500 (502 other companies) |
|---|---|---|---|
| Revenue growth, latest fiscal year | +8.9% | +7.1% | +7.0% |
| Net margin, latest fiscal year | 32.9% | 12.9% | 12.9% |
| Share price change, 1 year | +19.8% | +19.8% | +5.6% |
Vertex Pharmaceuticals: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Vertex Pharmaceuticals included, are the last regular-session prices of October 19, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, 1-year price change 59/490; the reasons below can overlap. 12 are left out of the price figure because our archive holds no comparable close for them. The S&P 500 price figure is the middle company's change, not the index's return.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.
Source: Wikipedia — Vertex Pharmaceuticals
- Headquarters
- Boston, Massachusetts From SEC filings, Oct 2026
Recent News (20)
-
Vortex Energy Corp. Announces Extension of Marketing Program VANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce, further to its news release…
-
Why is Vertex Pharmaceuticals stock sliding 4% today?
Why is Vertex Pharmaceuticals stock sliding 4% today?
-
Vertex reports pancreatic function recovery in young CF patients
Vertex reports pancreatic function recovery in young CF patients
-
-
Vertex appoints Debanjan Saha to board of directors as Class II director
Vertex appoints Debanjan Saha to board of directors as Class II director
-
Vortex Energy Completes Acquisition of the Meadows Project in Saskatchewan VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) ("Vortex" or the "Company") is pleased to announce that, further to its news re…
-
-
Vertex Appoints DataRobot CEO Debanjan Saha to Board of Directors New appointment strengthens Vertex's board with enterprise AI, data, and cloud leadership as the company advances its AI-first transformation New appointment strengthens Vertex's board with enterpris…
-
UBS raises Vertex stock price target to $615 on kidney drug trial
UBS raises Vertex stock price target to $615 on kidney drug trial
-
BMO reiterates Vertex stock rating on positive trial data
BMO reiterates Vertex stock rating on positive trial data
-
Vertex stock price target maintained at $641 by H.C. Wainwright
Vertex stock price target maintained at $641 by H.C. Wainwright
-
Vertex reports positive Phase 2b results for kidney disease drug
Vertex reports positive Phase 2b results for kidney disease drug
-
Vortex Energy Enters Into Asset Purchase Agreement to Acquire the Meadows Project in Saskatchewan VANCOUVER, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that it has entered into an…
-
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool
-
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? Currently.com
-
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
-
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? Yahoo Finance
-
Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference
Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference
-
Vertex Pharmaceuticals Incorporated (VRTX): Crinetics Acquisition Creates a New Growth Engine Beyond Cystic Fibrosis
Vertex Pharmaceuticals Incorporated (VRTX): Crinetics Acquisition Creates a New Growth Engine Beyond Cystic Fibrosis
-
Strong Core Business, Raised Guidance Push Vertex Pharmaceuticals Higher
Strong Core Business, Raised Guidance Push Vertex Pharmaceuticals Higher
More Health Care stocks
- TMO Thermo Fisher Scientific
- UHS Universal Health Services
- UNH UnitedHealth Group
- VEEV Veeva Systems
- VTRS Viatris
- WAT Waters Corporation
- WST West Pharmaceutical Services
- ZBH Zimmer Biomet